Assessment of the Efficacy and Tolerance of Drepanoalpha® in the Management of Sickle Cell Disease in Kinshasa (DR Congo): About Ten Cases

Aims: The aim of this study is to assess the efficacy and safety of Drepanoalpha®, a nutraceutical used in the management of sickle cell disease in DR Congo.

Study Design: Drepanoalpha® to ten sickle patients, evaluation of parameters before and after treatment.

Place and Duration of Study: Department of Biology, Science faculty, university of Kinshasa, between Sept 2015 and July 2016.

Methodology: The ten selected cases were submitted to Drepanoalpha® for two months and the following parameters were observed before, during and after treatment: The hemoglobin rate, the number of crises, biochemical parameters such as the rate of urea, creatinine, bilirubin (total and direct) and transaminases (SGOT and SGPT). A clinical evaluation and monitoring of product safety signs was also carried out.

Results: The results show an increase in hemoglobin in all patients ranging from 19.2 to 42.9% and a total stop of crises. The product does not disturb the indicators of liver function (transaminases SGOT and SGPT, total and direct bilirubin) nor those of renal function (urea and creatinine). No adverse effects event such as vomiting, urticaria, pruritus, itching and diarrhea were observed.

Conclusion: According to this study, Drepanoalpha® increases the hemoglobin level in subjects treated leading to a cessation of sickle cell crisis. This drug does not alter liver and kidney functions and does not induce side effects in treated subjects, thus ensuring its safety.